Adenosine A 2 receptors modulate haloperidol-induced catalepsy in rats

Abstract

The effect of adenosine A 1 and A 2 receptor agonists and antagonists was investigated on haloperidol-induced catalepsy in rats. Pretreatment (i.p.) with the non-selective adenosine receptor antagonist, theophylline, or the selective adenosine A 2 receptor antagonist, 3,7-dimethyl-1-propargylxanthine (DMPX), significantly reversed haloperidol-induced catalepsy, whereas the selective adenosine A 1 receptor antagonists, 8-phenyltheophylline and 8-cyclopentyl-1,3-dipropylxanthine produced no effect. Similar administration of the adenosine A 2 receptor agonists, 5′-( N-cyclopropyl)-carboxamidoadenosine and 5′- N-ethylcarboxamidoadenosine (NECA), and the mixed agonists with predominantly A 1 site of action, N 6-(2-phenylisopropyl) adenosine or 2-chloroadenosine, potentiated haloperidol-induced catalepsy. Higher doses of the adenosine agonists produced catalepsy when given alone. However, N 6-cyclopentyladenosine, a highly selective adenosine A 1 receptor agonist, was ineffective in these respects. The per se cataleptic effect of adenosine agonists was blocked by DMPX and the centrally acting anticholinergic agent, scopolamine. Scopolamine also attenuated the potentiation of haloperidol-induced catalepsy by adenosine agonists. Further, i.c.v. administration of NECA and DMPX produced a similar effect as that produced after their systemic administration. These findings demonstrate the differential influence of adenosine A 1 and A 2 receptors on haloperidol-induced catalepsy and support the hypothesis that the functional interaction between adenosine and dopamine mechanisms might occur through adenosine A 2 receptors at the level of cholinergic neurons. The results suggest that adenosine A 2, but not A 1, receptor antagonists may be of potential use in the treatment of Parkinson's disease.